Novo Nordisk's new obesity drug trial data disappoints again
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...
Novo Nordisk's Ozempic successor disappointed Wall Street again
Novo Nordisk (NVO) released clinical trial results for its potential Ozempic successor on Monday, disappointing Wall Street ...
Novo Nordisk stock slides Monday on second-generation GLP-1 data
Novo Nordisk stock was down more than 8% Monday morning after the Danish drugmaker shared new data on its next-generation GLP ...
Novo Nordisk shares fall on weight-loss drug trial
Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.
India may need to wait longer for Wegovy, say pharma analysts
Introduction of a direct-to-patient delivery model for its weight-loss drug in the United States could potentially delay its ...
Devdiscourse42m
Novo Nordisk's CagriSema Trial Disappoints, Shares Plunge
Novo Nordisk's second late-stage trial data for its obesity drug candidate, CagriSema, failed to meet expectations, leading to significant stock losses. The trial demonstrated weight loss similar to ...
Novo Nordisk Stock Drops on New Obesity Drug Findings. Eli Lilly Stands to Gain.
The Danish company said the average weight loss was 15.7% for the new drug, CagriSema. The expectation had been about 25%.
The Print50m
Eli Lilly plans launch of weight-loss drug in emerging markets by 2026, CFO says
(Reuters) -Eli Lilly plans to launch its blockbuster diabetes and weight-loss drug, Mounjaro, in countries like China, India, Brazil and Mexico by 2026, Chief Financial Officer Lucas Montarce said on ...